Nrl knockdown by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice
Open accessThe DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Abstract
In retinitis pigmentosa, loss of cone photoreceptors leads to blindness, and preservation of cone function is a major therapeutic goal. However, cone loss is thought to occur as a secondary event resulting from degeneration of rod photoreceptors. Here we report a genome editing approach in which adeno-associated virus (AAV)-mediated CRISPR/Cas9 delivery to postmitotic photoreceptors is used to target the Nrl gene, encoding for Neural retina-specific leucine zipper protein, a rod fate determinant during photoreceptor development. Following Nrl disruption, rods gain partial features of cones and present with improved survival in the presence of mutations in rod-specific genes, consequently preventing secondary cone degeneration. In three different mouse models of retinal degeneration, the treatment substantially improves rod survival and preserves cone function. Our data suggest that CRISPR/Cas9-mediated NRL disruption in rods may be a promising treatment option for patients with retinitis pigmentosa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A dual rAAVs system (rAAV.RKp.SpCas9; rAAV.U7.gRNA-Nrl) rescued vision in three mouse lines of rod retinal degeneration (Crx-Nrl -/-; rd10 or Pde6b -/-; Rho -/-) by knocking out Nrl in one or both alleles [219].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [219]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In recent years, viral vectors have been extensively applied to deliver CRISPR cassettes in vitro and in vivo largely owing to their high efficiency in gene delivery and long-term stable transgene expression [34, 58, 65].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 1×
“47) 64 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762 · cited 2×
“In contrast, the CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 gene editing system can efficiently disrupt genes at desired loci, enabling complete gene KO 17 .”
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · cited 1×
“Five sequences with leading scores and three that were previously reported 23,24 (ET1 to ET8, see Supplementary Table 1 and Supplementary Fig.”
GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists
Eden, E., Navon, R., Steinfeld, I., Lipson, D., & Yakhini, Z. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-48 · Cited by 3,356
Human photoreceptor topography
Curcio, C. A., Sloan, K. R., Kalina, R. E., & Hendrickson, A. E. (1990) · Journal of Comparative Neurology · doi:10.1002/cne.902920402 · Cited by 3,167 · cited 1×
“Rods are dim-light-sensing neurons distributed throughout the retina with the highest densities just outside of the macula 2,4 , whereas cones respond to higher levels of light and mediate colour vision.”
Cited by
The next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities
Li, L., Hu, S., & Chen, X. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.031 · Cited by 415
“In recent years, viral vectors have been extensively applied to deliver CRISPR cassettes in vitro and in vivo largely owing to their high efficiency in gene delivery and long-term stable transgene expression [34, 58, 65].”
BackgroundAthanasiou, D., Aguila, M., Bellingham, J., Li, W., McCulley, C., Reeves, P. J., & Cheetham, M. E. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.002 · Cited by 373
CRISPR/Cas9 for cancer research and therapy
Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.04.001 · Cited by 328
Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.110 · Cited by 306
Konstantakos, V., Nentidis, A., Krithara, A., & Paliouras, G. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac192 · Cited by 241
“Experiments on these two diseases have been successfully undertaken by domain experts recently (75,76).”
BackgroundElimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9
Batra, R., Nelles, D. A., Pirie, E., Blue, S. M., Marina, R. J., Wang, H., Chaim, I. A., Thomas, J. D., Zhang, N., Nguyen, V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.010 · Cited by 252
“Reconstitution of these DNA-targeting systems in eukaryotic cells has supported powerful applications in genome editing and other DNA-level manipulations (Sheridan, 2017; Yu et al., 2017).”
BackgroundLipid nanoparticles for delivery of messenger RNA to the back of the eye
Patel, S., Ryals, R. C., Weller, K. K., Pennesi, M. E., & Sahay, G. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.04.015 · Cited by 260
Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges
Taha, E. A., Lee, J., & Hotta, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.013 · Cited by 259
Molecular Anatomy of the Developing Human Retina
Hoshino, A., Ratnapriya, R., Brooks, M. J., Chaitankar, V., Wilken, M. S., Zhang, C., Starostik, M. R., Gieser, L., La Torre, A., Nishio, M., et al. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.10.029 · Cited by 251
“…have emerged as promising treatments for retinopathy patients carrying specific genetic loss-of-function mutations (Dalkara et al., 2016; Scholl et al., 2016; Tabebordbar et al., 2016; Yu et al., 2017), and novel therapeutic designs are being attempted for broader disease and population spectrum.”
BackgroundSelf-citationChehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M., Shafieizadeh, M., Mahmoudi, E., Eskandari, F., Rashidi, M., Arshi, A., & Mokhtari-Farsani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-023-01925-5 · Cited by 251
Erratum: Gene therapy for neurological disorders: progress and prospects
Deverman, B. E., Ravina, B. M., Bankiewicz, K. S., Paul, S. M., & Sah, D. W. Y. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.158 · Cited by 248
In vivo gene delivery mediated by non-viral vectors for cancer therapy
Mohammadinejad, R., Dehshahri, A., Sagar Madamsetty, V., Zahmatkeshan, M., Tavakol, S., Makvandi, P., Khorsandi, D., Pardakhty, A., Ashrafizadeh, M., Ghasemipour Afshar, E., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.038 · Cited by 238
Schneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
Stemming retinal regeneration with pluripotent stem cells
Jin, Z.-B., Gao, M.-L., Deng, W.-L., Wu, K.-C., Sugita, S., Mandai, M., & Takahashi, M. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.11.003 · Cited by 213
“vival by disrupting Nrl expression in postmitotic photoreceptors (Yu et al., 2017).”
BackgroundEarly and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190
Efficient Strategies for Microglia Replacement in the Central Nervous System
Xu, Z., Rao, Y., Huang, Y., Zhou, T., Feng, R., Xiong, S., Yuan, T.-F., Qin, S., Lu, Y., Zhou, X., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108041 · Cited by 172
Bak, R. O., Gomez-Ospina, N., & Porteus, M. H. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.004 · Cited by 176
“In vivo AAV delivery of genome editing components that depend primarily on NHEJ have also been applied to genetic diseases of the central nervous system such as Huntington’s disease (HD) [50,51], an autosomal dominant form of retinitis pigmentosa [52], and Leber congenital amaurosis 10 [53].”
BackgroundGarafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
“Our focus in this manuscript is on gene augmentation for specific IRDs; the interesting topic of gene therapies designed to target multiple IRDs is not covered (for example, Yu et al., 2017).”
CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research
Yang, Y., Xu, J., Ge, S., & Lai, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649896 · Cited by 193
Lau, C.-H., & Suh, Y. (2017) · F1000Research · doi:10.12688/f1000research.11243.1 · Cited by 161
In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation
Moreno, A. M., Fu, X., Zhu, J., Katrekar, D., Shih, Y.-R. V., Marlett, J., Cabotaje, J., Tat, J., Naughton, J., Lisowski, L., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.017 · Cited by 159
Immunity to CRISPR Cas9 and Cas12a therapeutics
Chew, W. L. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1408 · Cited by 147
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review)
Rodríguez-Rodríguez, D. R., Ram�rez‐Sol�s, R., Garza‐Elizondo, M. A., Garza‐Rodr�guez, M., & Barrera-Saldaña, H. A. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4112 · Cited by 199
“It has also been applied in movement diseases, such as duchenne muscular dystrophy (169-172), in metabolic diseases, such as type I diabetes (173) and hypercholesterolemia (174), and in inherited diseases that affect vision, such as retinitis pigmentosa (175), among numerous others.”
BackgroundWei, T., Cheng, Q., Farbiak, L., Anderson, D. G., Langer, R., & Siegwart, D. J. (2020) · ACS Nano · doi:10.1021/acsnano.0c04707 · Cited by 135
Khoshandam, M., Soltaninejad, H., Mousazadeh, M., Hamidieh, A. A., & Hosseinkhani, S. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.027 · Cited by 152
A Self-Deleting AAV-CRISPR System for In Vivo Genome Editing
Li, A., Lee, C. M., Hurley, A. E., Jarrett, K. E., Giorgi, M. D., Lu, W., Balderrama, K. S., Doerfler, A. M., Deshmukh, H., Ray, A., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.11.009 · Cited by 143
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Wan, T., Niu, D., Wu, C., Xu, F.-J., Church, G., & Ping, Y. (2019) · Materials Today · doi:10.1016/j.mattod.2018.12.003 · Cited by 117
Li, P., Kleinstiver, B. P., Leon, M. Y., Prew, M. S., Navarro-Gomez, D., Greenwald, S. H., Pierce, E. A., Joung, J. K., & Liu, Q. (2018) · The CRISPR Journal · doi:10.1089/crispr.2017.0009 · Cited by 116
Non-Viral Delivery To Enable Genome Editing
Rui, Y., Wilson, D. R., & Green, J. J. (2019) · Trends in Biotechnology · doi:10.1016/j.tibtech.2018.08.010 · Cited by 113
“Viral vector cargo size limitations additionally limit efficacy particularly in AAV systems, which can necessitate editing enzymes and donor templates to be packaged into separate viral particles [16, 17].”
BackgroundCRISPR technologies for stem cell engineering and regenerative medicine
Hsu, M.-N., Chang, Y.-H., Truong, V. A., Lai, P.-L., Nguyen, T. K. N., & Hu, Y.-C. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107447 · Cited by 104
Chiu, W., Lin, T.-Y., Chang, Y.-C., Lai, H. I. A. M., Lin, S.-C., Ma, C., Yarmishyn, A. A., Lin, S.-C., Chang, K.-J., Chou, Y.-B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094534 · Cited by 116
“Consequently, the knockdown Nrl by AAV-mediated CRISPR-Cas9 in mice induced morphology and functional changes in rods, allowing the cells to overcome the degeneration progress [105].”
BackgroundCarrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 109
Gene therapy for visual loss: Opportunities and concerns
Lee, J. H., Wang, J.-H., Chen, J., Li, F., Edwards, T. L., Hewitt, A. W., & Liu, G. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.08.003 · Cited by 107
“Several proof-ofprinciple studies have shown promising potential for in vivo gene disruption by the CRISPR/Cas system to at least alleviate the severity of many hereditary ocular diseases in animal models (Bakondi et al., 2016; Courtney et al., 2016; Giannelli et al., 2018; Latella et al., 2016; Ruan et al., 2017; Wan…”
Hazafa, A., Mumtaz, M., Farooq, M. F., Bilal, S., Chaudhry, S. N., Firdous, M., Naeem, H., Ullah, M. O., Yameen, M., Mukhtiar, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118525 · Cited by 102
Koo, T., Park, S. W., Jo, D. H., Kim, D., Kim, J. H., Cho, H.-Y., Kim, J. H., Kim, J. H., & Kim, J. (2018) · Nature Communications · doi:10.1038/s41467-018-04175-y · Cited by 99
Self-citationVision rescue via unconstrained in vivo prime editing in degenerating neural retinas
Qin, H., Zhang, W., Zhang, S., Feng, Y., Xu, W., Jia, Q., Zhang, Q., Xu, C., Liu, S., Zhang, J., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20220776 · Cited by 102
“The IRDs, for example, have been widely considered an ideal target for CRISPR-based gene therapy (Anzalone et al., 2020; Choi et al., 2022; Jang et al., 2021; Jo et al., 2019; Maeder et al., 2019; Suh et al., 2021; Yu et al., 2017).”
BackgroundInfluentialBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“gRNA-Nrl) rescued vision in three mouse lines of rod retinal degeneration (Crx-Nrl-/-; rd10 or Pde6b-/-; Rho-/-) by knocking out Nrl in one or both alleles [219].”
BackgroundAdvances in CRISPR-Cas technology and its applications: revolutionising precision medicine
Azeez, S. S., Hamad, R. S., Hamad, B., Shekha, M. S., & Bergsten, P. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1509924 · Cited by 107
Zabaleta, N., Barberia, M., Martín-Higueras, C., Zapata‐Linares, N., Betancor, I., Rodríguez-Diaz, S., Martínez-Turrillas, R., Torella, L., Vales, Á., Olagüe, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07827-1 · Cited by 95
Rapid characterization of adeno-associated virus (AAV) gene therapy vectors by mass photometry
Wu, D., Hwang, P., Li, T., & Piszczek, G. (2022) · Gene Therapy · doi:10.1038/s41434-021-00311-4 · Cited by 90
“The rAAV8 vectors were obtained by the calcium phosphate transfection method as described previously [34].”
Self-citationRetinitis Pigmentosa: Novel Therapeutic Targets and Drug Development
Wu, K. Y., Kulbay, M., Toameh, D., Xu, A. Q., Kalevar, A., & Tran, S. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020685 · Cited by 90
Sanjurjo-Soriano, C., Erkilic, N., Baux, D., Mamaeva, D., Hamel, C. P., Meunier, I., Roux, A.-F., & Kalatzis, V. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.016 · Cited by 79
Mouse γ-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Qizhao, W., Zhuang, P., Huang, H., Li, L., Liu, L., Webber, H. C., Dalal, R., Siew, L., Fligor, C. M., Chang, K., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0102-20.2020 · Cited by 89
“CRISPR/Cas9 has been used for photoreceptor gene editing with photoreceptor-specific promoters (Yu et al., 2017; Maeder et al., 2019).”
BackgroundMethodMcCullough, K. T., Boye, S. L., Fajardo, D., Calabro, K., Peterson, J. J., Strang, C. E., Chakraborty, D., Gloskowski, S., Haskett, S., Samuelsson, S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.193 · Cited by 79
Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing
Tang, H., Zhao, X., & Jiang, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.001 · Cited by 83
“Physical methods mainly include electroporation, microinjection, hydrodynamic injection, ultrasound and magnetofection, while the viral vectors mainly includes adenovirus (AV), adeno-associated virus (AAV) and lentivirus (LV) [35-37].”
MethodCRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.003 · Cited by 74
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Rui, Y., Varanasi, M., Mendes, S., Yamagata, H. M., Wilson, D. R., & Green, J. J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.04.005 · Cited by 73
“7 kb) sometimes requires that different CRISPR components be packaged in separate viral particles, introducing complexity and potentially reducing efficacy.(6,7) Synthetic vectors are largely agnostic to cargo size, and several recent reports have demonstrated strategies for nonviral intracellular delivery of the CRIS…”
BackgroundCRISPR Gene Editing in the Kidney
Cruz, N. M., & Freedman, B. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.02.347 · Cited by 70
Application of Non-Viral Vectors in Drug Delivery and Gene Therapy
Ren, S., Wang, M., Wang, C., Wang, Y., Sun, C., Zeng, Z., Cui, H., & Zhao, X. (2021) · Polymers · doi:10.3390/polym13193307 · Cited by 76
RNA Editing as a Therapeutic Approach for Retinal Gene Therapy Requiring Long Coding Sequences
Fry, L. E., Peddle, C. F., Barnard, A. R., McClements, M. E., & MacLaren, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030777 · Cited by 65
“In the eye, this has been used to knockdown dominant genes in animal models [13–16], reprogram photoreceptors [17], target angiogenic factors [18] and excise a deep intronic splicing mutation in the CEP290 gene, a strategy moving forward to clinical trial this year [19].”
BackgroundDesign of AAV Vectors for Delivery of Large or Multiple Transgenes
Patel, A., Zhao, J., Duan, D., & Lai, Y. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_2 · Cited by 72
Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS
Deng, H., Zhai, H., Shi, Y., Liu, G., Lowry, J., Liu, B., Ryan, É. B., Yan, J., Yang, Y., Zhang, N., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-01942-4 · Cited by 69
Start codon disruption with CRISPR/Cas9 prevents murine Fuchs’ endothelial corneal dystrophy
Uehara, H., Zhang, X., Pereira, F., Narendran, S., Choi, S., Bhuvanagiri, S., Liu, J., Kumar, S. R., Bohner, A. D., Carroll, L. S., et al. (2021) · eLife · doi:10.7554/elife.55637 · Cited by 65
Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease
Germino-Watnick, P., Hinds, M., Le, A., Chu, R., Liu, X., & Uchida, N. (2022) · Cells · doi:10.3390/cells11111843 · Cited by 68
Zhu, J., Ming, C., Fu, X., Duan, Y., Hoang, D. A., Rutgard, J., Zhang, R., Wang, W., Hou, R., Zhang, D., et al. (2017) · Cell Research · doi:10.1038/cr.2017.57 · Cited by 62
Delivery Approaches for Therapeutic Genome Editing and Challenges
Ates, I., Rathbone, T., Stuart, C., Bridges, P. H., & Cottle, R. N. (2020) · Genes · doi:10.3390/genes11101113 · Cited by 63
“In a study using AAV delivery for CRISPR-Cas9, the IVS26 intronic mutation in the CEP290 that causes Leber congenital amaurosis-10 was removed in a large deletion [107], demonstrating the applicability of the therapeutic approach for large gene deletions.”
BackgroundCRISPR/Cascade 9-Mediated Genome Editing-Challenges and Opportunities
Roy, B., Zhao, J. C., Yang, C., Luo, W., Xiong, T., Li, Y., Fang, X., Gao, G., Singh, C. O., Madsen, L., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00240 · Cited by 66
A multi-omics atlas of the human retina at single-cell resolution
Liang, Q., Cheng, X., Wang, J., Owen, L. A., Shakoor, A., Lillvis, J. L., Zhang, C., Farkas, M. H., Kim, I. K., Li, Y., et al. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100298 · Cited by 78
Progress and challenges towards CRISPR/Cas clinical translation
Rosenblum, D., Gutkin, A., Dammes, N., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.004 · Cited by 63
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 65
“Viral vectors including adenovirus, adeno-associated virus and lentivirus [61–63], and physical methods like electroporation [64], microinjection [65], hydrodynamic injection [66] and ultrasound [67], are relatively well-established strategies for delivering CRISPR/ Cas systems [68].”
MethodCRISPR/Cas9 cleavage efficiency regression through boosting algorithms and Markov sequence profiling
Peng, H., Zheng, Y., Blumenstein, M., Tao, D., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty298 · Cited by 57
“Gene editing investigations on these two diseases have been successfully undertaken by domain experts recently (Yu et al., 2017; De Ravin et al., 2017).”
BackgroundPeng, H., Zheng, Y., Zhao, Z., Liu, T., & Li, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty558 · Cited by 60
Development of Highly Efficient Dual‐AAV Split Adenosine Base Editor for In Vivo Gene Therapy
Chen, Y., Zhi, S., Liu, W., Wen, J., Hu, S., Cao, T., Sun, H., Li, Y., Huang, L., Liu, Y., et al. (2020) · Small Methods · doi:10.1002/smtd.202000309 · Cited by 57
Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect
Chuang, Y.-F., Phipps, A. J., Lin, F., Hecht, V. F. G., Hewitt, A. W., Wang, P., & Liu, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03725-2 · Cited by 57
Allele-specific editing ameliorates dominant retinitis pigmentosa in a transgenic mouse model
Patrizi, C., Llado, M., Benati, D., Iodice, C., Marrocco, E., Guarascio, R., Surace, E. M., Cheetham, M. E., Auricchio, A., & Recchia, A. (2021) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2021.01.006 · Cited by 47
Restoration of RPGR expression in vivo using CRISPR/Cas9 gene editing
Gumerson, J., Alsufyani, A., Yu, W., Lei, J., Sun, X., Dong, L., Wu, Z., & Li, T. (2021) · Gene Therapy · doi:10.1038/s41434-021-00258-6 · Cited by 54
“Dual AAV vectors were generated: one containing a Streptococcus pyogenes Cas9 (SpCas9) driven by the rhodopsin kinase (RK) promoter [34] and another containing both the RPGR-targeted sgRNA (see above) driven by the U6 promoter and tdTomato reporter gene driven by RK promoter.”
MethodSelf-citationCRISPR innovations in tissue engineering and gene editing
Razavi, Z.-S., Soltani, M., Souri, M., & van Wijnen, A. J. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123120 · Cited by 52
Pathways and disease-causing alterations in visual chromophore production for vertebrate vision
Kiser, P. D., & Palczewski, K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.014405 · Cited by 52
“(164) disrupted NRL using CRISPR-Cas9 in three mouse models of retinal degeneration and observed a significant improvement in rod and cone survival attributable to altered gene expression patterns.”
MethodSun, D., Sun, Z., Jiang, H., Vaidya, A. M., Xin, R., Ayat, N. R., Schilb, A. L., Qiao, P. L., Han, Z., Naderi, A., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00856 · Cited by 49
Cuevas, E., Holder, D., Alshehri, A. H., Tréguier, J., Lakowski, J., & Sowden, J. (2021) · Stem Cells · doi:10.1002/stem.3325 · Cited by 34
Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases
Yu, W., & Wu, Z. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.011 · Cited by 50
Self-citationKe, Y., Fan, X., Hao, R., Dong, L., Xue, M., Tan, L., Yang, C., Li, X., & Ren, X. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02034-6 · Cited by 51
Self-citationCRISPR-Cas System: The Current and Emerging Translational Landscape
Bhokisham, N., Laudermilch, E., Traeger, L. L., Bonilla, T. D., Ruíz-Estévez, M., & Becker, J. R. (2023) · Cells · doi:10.3390/cells12081103 · Cited by 55
Song, M. (2017) · Biotechnology Progress · doi:10.1002/btpr.2484 · Cited by 43
DZNep inhibits H3K27me3 deposition and delays retinal degeneration in the rd1 mice
Zheng, S., Xiao, L., Liu, Y., Wang, Y., Cheng, L. Z., Zhang, J., Yan, N., & Chen, D. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0349-8 · Cited by 47
Ratican, S., Osborne, A., & Martin, K. R. G. (2018) · Neural Plasticity · doi:10.1155/2018/7108948 · Cited by 49
Personalised genome editing – The future for corneal dystrophies
Moore, T., Christie, K. A., Marshall, J., & Nesbit, M. A. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.01.004 · Cited by 45
“pyogenes Cas9 and sgRNA to postmitotic photoreceptor cells in vivo in 3 separate retinal degeneration mouse models (Yu et al., 2017).”
BackgroundPaving the way towards precise and safe CRISPR genome editing
Śledziński, P., Dabrowska, M., Nowaczyk, M., & Olejniczak, M. (2021) · Biotechnology Advances · doi:10.1016/j.biotechadv.2021.107737 · Cited by 45
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
Wang, C., Sun, W., Ling, S., Wang, Y., Wang, X., Meng, H., Li, Y., Yuan, X., Liu, R., Liu, R., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.09.030 · Cited by 42
Critical review on where CRISPR meets molecular diagnostics
Lau, A., Ren, C. L., & Lee, L. P. (2020) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/abbf5e · Cited by 43
“Therapeutic gene therapies are being explored to treat diseases through mechanisms such as disruption [13], deletion [14], and insertion [15] into genes via”
BackgroundGenome-editing strategies for treating human retinal degenerations
Quinn, J., Musa, A., Kantor, A., McClements, M. E., Cehajic-Kapetanovic, J., MacLaren, R. E., & Xue, K. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.231 · Cited by 41
“More generic approaches for slowing disease progression or restoring visual function in IRDs are also under exploration, including AAV-mediated neuroprotection55 and reprogramming of photoreceptors through AAV-CRISPR/Cas9-mediated knockdown of NRL.56 Moreover, targeting common neurodegenerative and neuroinflammatory d…”
Mookherjee, S., Chen, H. Y., Isgrig, K., Yu, W., Hiriyanna, S., Levron, R., Li, T., Colosi, P., Chien, W., Swaroop, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.043 · Cited by 41
“(E) Immunoblots showing lower CEP290rd16 expression in the retinal lysate of mice receiving CRISPR-Cep290 treatment. b-Actin was used as a loading control.”
BackgroundMethodResultInfluentialSelf-citationZhang, X., Leavey, P. J., Appel, H., Makrides, N., & Blackshaw, S. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.06.002 · Cited by 43
CRISPR/Cas9 Delivery Mediated with Hydroxyl‐Rich Nanosystems for Gene Editing in Aorta
Zhang, X., Chen, X., Gao, S., Li, P., Kong, Y., Li, T., Li, Y., Xu, F., & Du, J. (2019) · Advanced Science · doi:10.1002/advs.201900386 · Cited by 42
Self-citationGene Editing Preserves Visual Functions in a Mouse Model of Retinal Degeneration
Vagni, P., Perlini, L. E., Chenais, N. A. L., Marchetti, T., Parrini, M., Contestabile, A., Cancedda, L., & Ghezzi, D. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00945 · Cited by 45
Gene-agnostic therapeutic approaches for inherited retinal degenerations
John, M. C., Quinn, J., Hu, M. L., Cehajic‐Kapetanovic, J., & Xue, K. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1068185 · Cited by 43
“Approaches utilising photoreceptor cells taken from Nrl−/− mice, in which all rods become converted to cone-like cells, showed integration and photopic response restoration in Cpfl1 mice though integration rates were low ( 1”
BackgroundResultInfluentialSanjurjo-Soriano, C., & Kalatzis, V. (2018) · Neural Plasticity · doi:10.1155/2018/5056279 · Cited by 42
“Subretinal injection of the dual AAV system prevented cone degeneration and restored the survival of rod photoreceptors in three different genetic mouse models of retinal degeneration (Rho mice, Nrl-LEGFP/Rd10 mice, and in RHO P347S transgenic mice) [123].”
CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing
Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.013 · Cited by 40
“However, a localized injection, such as subretinal or intravitreal injections, is favored while administering AAVs containing CRISPR/Cas components into the mouse retina.(85,143,144) Although most of the in vivo methods have the potential to be extended to human studies, the high dosage required to achieve clinically…”
BackgroundIron-Chelating Drugs Enhance Cone Photoreceptor Survival in a Mouse Model of Retinitis Pigmentosa
Wang, K., Peng, B., Xiao, J., Weinreb, O., Youdim, M. B. H., & Lin, B. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22096 · Cited by 38
García-Delgado, A. B., Valdés-Sánchez, L., Morillo-Sánchez, M. J., Ponte, B., Diaz-Corrales, F. J. J., & de la Cerda, B. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01843-z · Cited by 40
“Although this new technique has been successfully used ex vivo to treat some types of haematological cancers, research in retinal diseases is currently at the preclinical level [81, 82].”
MethodThe application and progression of CRISPR/Cas9 technology in ophthalmological diseases
Hu, X., Zhang, B., Li, X., Li, M., Wang, Y., Dan, H., Zhou, J., Wei, Y., Ge, K., Li, P., et al. (2022) · Eye · doi:10.1038/s41433-022-02169-1 · Cited by 42
“[60] hypothesized that the loss of cone photoreceptors leads to blindness in RP patients, presumably as a secondary change after rod photoreceptor degeneration.”
BackgroundEnhancing the Therapeutic Potential of Mesenchymal Stem Cells with the CRISPR-Cas System
Filho, D. M., Ribeiro, P. D. C., de Oliveira, L. F., dos Santos, A. L. T., Parreira, R. C., Pinto, M. C. X., & Resende, R. R. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09897-0 · Cited by 38
“…et al., 2016 [38] Cancer Mouse Koo et al., 2017 [39] Muscular dystrophy Human Li et al., 2015 [40] Neurological disorders Human Wang et al., 2017 [41] Respiratory disorders Human Firth et al., 2015 [42] Skin disease Human Hainzl et al., 2017 [43] Eye diseases Mouse Yu et al., 2017 [44] Fig.”
BackgroundCRISPR technology for genome editing
Bhattacharjee, G., Mani, I., Gohil, N., Khambhati, K., Braddick, D., Panchasara, H., & Singh, V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-819178-1.00007-1 · Cited by 38
Advancements in CRISPR/Cas systems for disease treatment
Xu, Y., Le, H., Wu, Q., Wang, N., & Gong, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.007 · Cited by 35
“By targeting the Nrl gene, which encodes a protein specific to the neural retina, researchers have enhanced the survival of rod cells and improved recovery from retinal degeneration across three animal models 160 .”
Metadata
- Authors
- Yu, W., Mookherjee, S., Chaitankar, V., Hiriyanna, S., Kim, J.-W., Brooks, M., Ataeijannati, Y., Sun, X., Dong, L., Li, T., Swaroop, A., & Wu, Z.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Wu, Zhijian
- ORCID
- Venue
- Nature Communications
- Published
- 2017-03-14
- Volume
- 8
- Issue
- 1
- Pages
- 14716-14716
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC5355895
- OpenAlex
- W2620315774
- Cited by
- 271
- References
- 70
- Citations by year
- 2026: 7 · 2025: 11 · 2024: 23 · 2023: 21 · 2022: 35 · 2021: 41 · 2020: 38 · 2019: 24 · 2018: 51 · 2017: 20
- FWCI
- 14.86
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health
- National Eye Institute
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- retinitis pigmentosa, CRISPR/Cas9 genome editing, AAV gene delivery, rod photoreceptors, cone photoreceptors, retinal degeneration, gene therapy, mouse model
- MeSH terms
- Gene Editing, Dependovirus, Animals, Cell Survival, Eye Proteins, Retinal Degeneration, Retinitis Pigmentosa, Retinal Rod Photoreceptor Cells, Retinal Cone Photoreceptor Cells, Basic-Leucine Zipper Transcription Factors, Mice, Gene Knockdown Techniques, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.